Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
OSR Holdings, Inc. incurred loan of $200,000 with Bellevue Global Life Sciences Investors LLC maturing earlier of December 31, 2024 or the date on which the Company consummates an initial business combination.
- Instrument
- loan
- Principal
- $200,000
- Counterparty
- Bellevue Global Life Sciences Investors LLC
- Maturity
- earlier of December 31, 2024 or the date on which the Company consummates an initial business combination
- Event
- incurrence
Exact text from the filing
On June 23, 2023, Bellevue Life Sciences Acquisition Corp., a Delaware corporation and blank check company (the “Company”), issued an unsecured promissory note (the “Note”) in the principal amount of $200,000 to Bellevue Global Life Sciences Investors LLC, the Company’s initial public offering sponsor (the “Sponsor”).
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
OSR Holdings, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)(B)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- audit committee
- Rules
- 5605(c)(2)(A), 5605(c)(4)(B)
Exact text from the filing
June 27, 2023 that the Company is not currently in compliance with Nasdaq Listing Rule 5605(c)(2)(A) (the “Listing Rule”), but that it intends to regain compliance within the cure period provided by section (c)(4)(B) of the Listing Rule. The Listing Rule requires the Audit Committee (the “Audit Committee”) of the Company’s Board of Directors (the “Board”) be composed of at least three members, each of whom must meet independence requirements under the Nasdaq Listing Rules and the Securities Exchange Act of 1934, as amended. Upon the effective date of Mr. Euh’s resignation from the Company’s
View on SEC.gov